Price T Rowe Associates Inc. MD Acquires 180,140 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Price T Rowe Associates Inc. MD lifted its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 16.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,295,025 shares of the company’s stock after purchasing an additional 180,140 shares during the period. Price T Rowe Associates Inc. MD owned 1.84% of ORIC Pharmaceuticals worth $10,452,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Silverarc Capital Management LLC increased its position in ORIC Pharmaceuticals by 7.2% in the 4th quarter. Silverarc Capital Management LLC now owns 1,178,300 shares of the company’s stock valued at $9,509,000 after acquiring an additional 78,810 shares in the last quarter. Diadema Partners LP acquired a new stake in shares of ORIC Pharmaceuticals in the fourth quarter valued at approximately $1,729,000. Tower Research Capital LLC TRC raised its position in ORIC Pharmaceuticals by 1,048.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,661 shares of the company’s stock worth $118,000 after purchasing an additional 13,384 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in ORIC Pharmaceuticals by 15.3% during the 4th quarter. MetLife Investment Management LLC now owns 41,608 shares of the company’s stock worth $336,000 after buying an additional 5,530 shares in the last quarter. Finally, Natixis bought a new position in ORIC Pharmaceuticals in the 4th quarter valued at $645,000. 95.05% of the stock is owned by institutional investors.

ORIC Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC opened at $5.67 on Friday. The company has a 50 day moving average price of $6.17 and a two-hundred day moving average price of $8.21. The company has a market capitalization of $403.05 million, a PE ratio of -3.12 and a beta of 1.38. ORIC Pharmaceuticals, Inc. has a 52 week low of $3.90 and a 52 week high of $14.67.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.01. On average, sell-side analysts forecast that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

ORIC has been the subject of a number of recent research reports. Wedbush restated an “outperform” rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Thursday, March 20th. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $18.86.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.